Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
254 Results
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.
CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).